Associated Genetic Biomarkers
NCI Definition: An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix. 
Wilms tumors most frequently harbor alterations in TP53, MYCN, WT1, AMER1, and CTNNB1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, CTNNB1 Mutation, and TP53 Exon 8 Mutation are the most common alterations in Wilms tumor .
There are 7 clinical trials for Wilms tumor, of which 6 are open and 1 is completed or closed. Of the trials that contain Wilms tumor as an inclusion criterion, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is no phase specified (1 open).
MYCN, PD-L1, and TMB-High are the most frequent gene inclusion criteria for Wilms tumor clinical trials .
Taa-specific t cells, cabozantinib, and entinostat are the most common interventions in Wilms tumor clinical trials.
Significant Genes in Wilms Tumor
MET is an inclusion eligibility criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET status and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.